NCT05414864View on ClinicalTrials.gov

Insomnia Prevalence and Treatment Impact on Systemic Hypertension

PHASE4TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

May 1, 2022

Primary Completion Date

July 31, 2022

Study Completion Date

September 30, 2022

Conditions
InsomniaHypertension
Interventions
DRUG

Ramelteon (RozeremR)

8mg daily

BEHAVIORAL

sleep hygiene

sleep behavioral guidelines

Trial Locations (1)

05403-900

Heart Institute (InCor), São Paulo

Sponsors

Collaborators (1)

Takeda
All Listed Sponsors
collaborator

Takeda

INDUSTRY

lead

University of Sao Paulo

OTHER